Preclinical Glaucoma CRO Services
From IOP elevation and optic nerve injury to excitotoxic RGC loss – robust in vivo models, publication-ready data. Integrated mouse glaucoma models with multimodal functional and structural readouts to accelerate your glaucoma drug discovery.
Preclinical Glaucoma Models & Custom Study Services
Glaucoma is a leading cause of irreversible blindness worldwide, driven by progressive degeneration of retinal ganglion cells (RGCs) and their axons. To support drug discovery and mechanism-of-action studies, we provide a portfolio of well-characterized mouse glaucoma models that capture different aspects of disease pathology, including elevated intraocular pressure (IOP), optic nerve injury, retinal ischemia, and excitotoxic RGC loss.
Our platform combines robust in vivo models with advanced functional and structural readouts (ERG, VEP,
OCT, immunofluorescence, histology) to deliver translational data packages tailored to your program.
{{ item.title }}
{{static_tabs[0].title}}
Disease-Relevant Induced Glaucoma Models
| Model name | Key Mechanism | Pathology & Clinical Relevance | Action |
|---|---|---|---|
| Magnetic Bead Occlusion Induced Glaucoma | Anterior chamber injection of magnetic beads to obstruct aqueous outflow | Mimics key pathological features of primary open-angle glaucoma (POAG). |
|
| Optic Nerve Crush Injury induced Glaucoma | Mechanical compression of the optic nerve | Mimics optic nerve injury and advanced-stage glaucoma–associated neurodegeneration. |
|
| Ischemia-reperfusion induced Glaucoma | Transient elevation of IOP to restrict retinal blood flow, followed by reperfusion | Mimics ischemia–reperfusion–associated retinal injury relevant to acute glaucoma and ocular ischemic conditions. |
|
| NMDA-induced Glaucoma | Intravitreal injection of NMDA to overactivate glutamate receptors | Mimics pressure-independent retinal ganglion cell degeneration relevant to normal-tension glaucoma (NTG). |
|
Relevant Model
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
；
|
+
|
Next Page
{{static_tabs[1].title}}
Our in vivo pharmacology services integrate disease-relevant glaucoma models
with functional and structural assessments, enabling robust evaluation of therapeutic efficacy,
neuroprotection, and disease progression.
Precision Drug Administration for Glaucoma Research
Our experienced ophthalmic research team specializes in precision ocular drug administration to
support glaucoma pharmacology and mechanism-of-action studies. We employ validated intraocular
injection techniques to ensure accurate, reproducible, and localized delivery of therapeutic
candidates to anterior and posterior eye segments.
Ocular Delivery Routes:
- Intracameral Injection – targeted delivery to the anterior chamber for intraocular pressure–related studies
- Intravitreal Injection – direct delivery to the vitreous cavity for retinal ganglion cell (RGC) and optic nerve–related evaluations
In Vivo Functional & Structural Readouts
Functional Assessments
- Flash Electroretinography (ERG)
- Visual Evoked Potential (VEP)
- Photopic Negative Response (PhNR)
Structural Assessments
- Coherence Tomography (OCT)
- Ganglion Cell Layer (GCL + IPL) thickness
{{static_tabs[2].title}}
To enable rigorous evaluation of retinal neurodegeneration, we provide comprehensive ex vivo and
post-mortem analyses focusing on retinal ganglion cell survival, axonal integrity, and retinal
structural alterations.
| Analysis Category | Specific Services | Key Applications & Targets in Glaucoma Research |
|---|---|---|
| Pathology & Biomarker Analysis | Immunofluorescence (Flat-mount/Section) | Quantify RGC survival using specific markers like TUBB3 (axon integrity) and RBPMS (RGC soma count). |
| Pathology & Morphology | Histology (H&E) | Measure total retinal thickness and observe morphological changes in retinal layers. |
| Physiological & Biochemical Analysis | Electroretinogram (ERG)， Visual Evoked Potential (VEP)，photopic negative response (PhNR) | Assess functional integrity of retinal ganglion cells and optic nerve pathways by measuring electrical responses to visual stimuli. |
Case Studies
{{ item.label }}
{{v2.label}}
{{v2.title}}
{{item.title}}
Why Partner with Cyagen?
Disease-relevant glaucoma models
We offer validated induced glaucoma models that closely mimic clinical IOP elevation, optic nerve damage, and RGC loss.
Customizable study design
We tailor model selection, dosing regimens, and endpoints to align with your mechanism of action and translational goals.
Experienced pharmacology team
Our scientists bring extensive experience in CNS and ocular pharmacology to generate robust, decision-ready data packages.
Related Resources
Events & Webinars
Life Science Exhibits at Technology Square, Cambridge
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
Accelerating Alzheimer's Research Using Advanced iPSC Platforms
View Details
Resource Valut
Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
